Post by Cytiva

Cell therapies don’t behave like traditional biologics. Batches are smaller, patient populations are tighter, and timelines matter.​ Earlier this year, the FDA signaled a more flexible, lifecycle‑based approach to CMC oversight for these therapies. A few months on, the real question is how that shift is starting to change manufacturing thinking – from when specifications are set, to how validation is justified, to where teams avoid unnecessary lock‑in.​ We break down what this direction could mean for cell therapy manufacturing, and how teams can plan for evolving expectations while keeping quality front and center.​ Read more: https://okt.to/sByrQb #CellTherapy #GeneTherapy #Biomanufacturing #CMC #RegulatoryScience